Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
DSNKY DAIICHI SANKYO COMPANY LIMITED SPON ADR EA REPR 1 ORD JPY0.00 LEVEL I
32.790
-0.870-2.58%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Sunao ManabeDirector, President and Chief Executive Officer------68male06/27/2022
Mr. Masahiko OhtsukiDirector, Senior Executive Officer, Chief Information Officer, Global Management Structure and Head, Digital Transformation Management Division------63male06/27/2022
Mr. Hiroyuki OkuzawaaDirector, Chief Financial Officer, Senior Executive Officer, President of ASCA Company and Head, Corporate Planning & Management Division------60male06/27/2022
Mr. Shoji HirashimaDirector, Senior Executive Officer and Head, Japan Business Unit------61male06/27/2022
Mr. Takashi FukuokaDirector, Executive Officer and Head, Corporate Strategy Division------61male06/27/2022
Ms. Sawako NoharaIndependent Director------64female06/27/2022
Mr. Kazuaki KamaIndependent Director------74male06/27/2022
Mr. Yasuhiro KomatsuIndependent Director------65male06/27/2022
Mr. Noritaka UjiChairperson of Board------73male06/27/2022
Company Overview More
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
CEO: Mr. Sunao Manabe
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist